<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39333473</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Predicting COVID-19 booster immunogenicity against future SARS-CoV-2 variants and the benefits of vaccine updates.</ArticleTitle><Pagination><StartPage>8395</StartPage><MedlinePgn>8395</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">8395</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-024-52194-9</ELocationID><Abstract><AbstractText>The ongoing evolution of the SARS-CoV-2 virus has led to a move to update vaccine antigens in 2022 and 2023. These updated antigens were chosen and approved based largely on in vitro neutralisation titres against recent SARS-CoV-2 variants. However, unavoidable delays in vaccine manufacture and distribution meant that the updated booster vaccine was no longer well-matched to the circulating SARS-CoV-2 variant by the time of its deployment. Understanding whether the updating of booster vaccine antigens improves immune responses to subsequent SARS-CoV-2 circulating variants is a major priority in justifying future vaccine updates. Here we analyse all available data on the immunogenicity of variants containing SARS-CoV-2 vaccines and their ability to neutralise later circulating SARS-CoV-2 variants. We find that updated booster antigens give a 1.4-fold [95% CI: 1.07-1.82] greater increase in neutralising antibody levels when compared with a historical vaccine immunogen. We then use this to predict the relative protection that can be expected from an updated vaccine even when the circulating variant has evolved away from the updated vaccine immunogen. These findings help inform the rollout of future booster vaccination programmes.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cromer</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-5276-5094</Identifier><AffiliationInfo><Affiliation>Kirby Institute, University of New South Wales, Sydney, NSW, Australia. d.cromer@unsw.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reynaldi</LastName><ForeName>Arnold</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Ainslie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schlub</LastName><ForeName>Timothy E</ForeName><Initials>TE</Initials><Identifier Source="ORCID">0000-0001-7746-9649</Identifier><AffiliationInfo><Affiliation>Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juno</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0002-9072-1017</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wheatley</LastName><ForeName>Adam K</ForeName><Initials>AK</Initials><Identifier Source="ORCID">0000-0002-5593-9387</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kent</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-8539-4891</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khoury</LastName><ForeName>David S</ForeName><Initials>DS</Initials><Identifier Source="ORCID">0000-0002-2663-1551</Identifier><AffiliationInfo><Affiliation>Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davenport</LastName><ForeName>Miles P</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0002-4751-1831</Identifier><AffiliationInfo><Affiliation>Kirby Institute, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1173528</GrantID><Agency>Department of Health | National Health and Medical Research Council (NHMRC)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="Y">Immunization, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>9</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>9</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>23</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39333473</ArticleId><ArticleId IdType="pmc">PMC11436652</ArticleId><ArticleId IdType="doi">10.1038/s41467-024-52194-9</ArticleId><ArticleId IdType="pii">10.1038/s41467-024-52194-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>FDA. Coronavirus (COVID-19) Update: FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines (18 April 2023); https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-changes-simplify-use-bivalent-mrna-covid-19-vaccines</Citation></Reference><Reference><Citation>FDA. FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants (11 September 2023); https://www.fda.gov/news-events/press-announcements/fda-takes-action-updated-mrna-covid-19-vaccines-better-protect-against-currently-circulating</Citation></Reference><Reference><Citation>WHO. Statement on the Antigen Composition of COVID-19 vaccines (18 May 2023); https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines</Citation></Reference><Reference><Citation>Pfizer. Vaccines and Related Biological Products Advisory Committee June 28, 2022 Meeting Presentation—Pfizer/BioNTech COVID-19 Omicron-Modified Vaccine Options (2022).</Citation></Reference><Reference><Citation>Pfizer. Vaccines and Related Biological Products Advisory Committee June 15, 2023 Meeting Presentation- Pfizer: 2023–2024 COVID19 Vaccine Formula—Clinical and Preclinical Supportive Data (2023).</Citation></Reference><Reference><Citation>Moderna. Vaccines and Related Biological Products Advisory Committee June 28, 2022 Meeting Presentation—mRNA-1273.214 Moderna COVID-19 Investigational Bivalent Vaccine (28 June 2022); https://www.fda.gov/media/159492/download</Citation></Reference><Reference><Citation>Moderna. Vaccines and Related Biological Products Advisory Committee June 28, 2022 Meeting Presentation—Moderna COVID-19 Variant Vaccines (15 June 2023); https://www.fda.gov/media/169539/download</Citation></Reference><Reference><Citation>Offit, P. A. Bivalent Covid-19 vaccines—a cautionary tale. N. Engl. J. Med388, 481–483 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36630616</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsakos, M. &amp; Ellebedy, A. H. Immunological imprinting: understanding COVID-19. Immunity56, 909–913 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10113596</ArticleId><ArticleId IdType="pubmed">37105169</ArticleId></ArticleIdList></Reference><Reference><Citation>Branche, A. R. et al. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. Nat. Med.29, 2334–2346 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10504073</ArticleId><ArticleId IdType="pubmed">37640860</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, D. J., Forrest, S., Ackley, D. H. &amp; Perelson, A. S. Variable efficacy of repeated annual influenza vaccination. Proc. Natl. Acad. Sci. USA96, 14001–14006 (1999).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24180</ArticleId><ArticleId IdType="pubmed">10570188</ArticleId></ArticleIdList></Reference><Reference><Citation>Addetia, A. et al. Neutralization, effector function and immune imprinting of Omicron variants. Nature621, 592–601 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10511321</ArticleId><ArticleId IdType="pubmed">37648855</ArticleId></ArticleIdList></Reference><Reference><Citation>Branche, A. R. et al. Immunogenicity of the BA.1 and BA.4/BA.5 severe acute respiratory syndrome coronavirus 2 bivalent boosts: preliminary results from the COVAIL randomized clinical trial. Clin. Infect. Dis.77, 560–564 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10443997</ArticleId><ArticleId IdType="pubmed">37036397</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr, E. J. et al. Neutralising immunity to Omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection. Lancet Infect. Dis.23, 781–784 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10241485</ArticleId><ArticleId IdType="pubmed">37290472</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias, S. et al. A bivalent Omicron-containing booster vaccine against Covid-19. N. Engl. J. Med.387, 1279–1291 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9511634</ArticleId><ArticleId IdType="pubmed">36112399</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias, S. et al. Safety, immunogenicity and antibody persistence of a bivalent beta-containing booster vaccine against COVID-19: a phase 2/3 trial. Nat. Med.28, 2388–2397 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671805</ArticleId><ArticleId IdType="pubmed">36202997</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias, S. et al. Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results. Nat. Med.29, 2325–2333 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10504066</ArticleId><ArticleId IdType="pubmed">37653342</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalkias, S. et al. Safety and immunogenicity of Omicron BA.4/BA.5 bivalent vaccine against Covid-19. Preprint at medRxiv10.1101/2022.12.11.22283166 (2022).</Citation></Reference><Reference><Citation>Chalkias, S. et al. Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines. J Infect Dis.230, e279–e286 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11326827</ArticleId><ArticleId IdType="pubmed">38349280</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier, A. Y. et al. Immunogenicity of BA.5 bivalent mRNA vaccine boosters. N. Engl. J. Med.388, 565–567 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9847505</ArticleId><ArticleId IdType="pubmed">36630611</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, J. et al. Substantial neutralization escape by SARS-CoV-2 Omicron variants BQ.1.1 and XBB.1. N. Engl. J. Med.388, 662–664 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878581</ArticleId><ArticleId IdType="pubmed">36652339</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis-Gardner, M. E. et al. Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster. N. Engl. J. Med.388, 183–185 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9812288</ArticleId><ArticleId IdType="pubmed">36546661</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravenstein, S. et al. Durability of immunity and clinical protection in nursing home residents following bivalent SARS-CoV-2 vaccination. eBioMedicine105, 105180 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11215210</ArticleId><ArticleId IdType="pubmed">38861869</ArticleId></ArticleIdList></Reference><Reference><Citation>He, Q. et al. The bivalent COVID-19 booster immunization after three doses of inactivated vaccine augments the neutralizing antibody response against circulating Omicron sublineages. J. Clin. Med.12, 146 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9821285</ArticleId><ArticleId IdType="pubmed">36614948</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, M. et al. Effect of hybrid immunity and bivalent booster vaccination on Omicron sublineage neutralisation. Lancet Infect. Dis.23, 25–28 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9721839</ArticleId><ArticleId IdType="pubmed">36480944</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang, N. et al. Bivalent mRNA vaccine improves antibody-mediated neutralization of many SARS-CoV-2 Omicron lineage variants. Preprint at bioRxiv10.1101/2023.01.08.523127 (2023).</Citation></Reference><Reference><Citation>Kawasuji, H. et al. Neutralizing antibody response of the wild-type/Omicron BA.1 bivalent vaccine as the second booster dose against Omicron BA.2 and BA.5. Microbiol. Spectr.11, e0513122 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10101054</ArticleId><ArticleId IdType="pubmed">36946738</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurhade, C. et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat. Med.29, 344–347 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36473500</ArticleId></ArticleIdList></Reference><Reference><Citation>Launay, O. et al. Immunogenicity and safety of beta-adjuvanted recombinant booster vaccine. N. Engl. J. Med.387, 374–376 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9258749</ArticleId><ArticleId IdType="pubmed">35767474</ArticleId></ArticleIdList></Reference><Reference><Citation>Pajon, R. et al. SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination. N. Engl. J. Med.386, 1088–1091 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8809504</ArticleId><ArticleId IdType="pubmed">35081298</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossler, A. et al. Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography. Nat. Commun.14, 5224 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10460376</ArticleId><ArticleId IdType="pubmed">37633965</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan, N. H. et al. Immunogenicity of bivalent Omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial. Lancet Infect. Dis.23, 901–913 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10188122</ArticleId><ArticleId IdType="pubmed">37088096</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell186, 279–286.e278 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9747694</ArticleId><ArticleId IdType="pubmed">36580913</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Q. et al. Antibody response to Omicron BA.4-BA.5 bivalent booster. N. Engl. J. Med.388, 567–569 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9847504</ArticleId><ArticleId IdType="pubmed">36630643</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, W. et al. Bivalent coronavirus disease 2019 vaccine antibody responses to Omicron variants suggest that responses to divergent variants would be improved with matched vaccine antigens. J. Infect. Dis.228, 439–443 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10428200</ArticleId><ArticleId IdType="pubmed">37279924</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou, J. et al. Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine. N. Engl. J. Med.388, 854–857 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9891359</ArticleId><ArticleId IdType="pubmed">36734885</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, J. et al. A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain. Nat. Commun.13, 6866 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9651894</ArticleId><ArticleId IdType="pubmed">36369243</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury, D. S. et al. Predicting the efficacy of variant-modified COVID-19 vaccine boosters. Nat. Med. 29, 574–578 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36864253</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med.27, 1205–1211 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Cromer, D. et al. Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis. Nat. Commun.14, 1633 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10036966</ArticleId><ArticleId IdType="pubmed">36964146</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, I. T. et al. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial. Lancet Infect. Dis.23, 1007–1019 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37348519</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin, D. Y. et al. Effectiveness of bivalent boosters against severe Omicron infection. N. Engl. J. Med.388, 764–766 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9933929</ArticleId><ArticleId IdType="pubmed">36734847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirsebom, F. C. M., Andrews, N., Stowe, J., Ramsay, M. &amp; Lopez Bernal, J. Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study. Lancet Infect. Dis.23, 1235–1243 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37453440</ArticleId></ArticleIdList></Reference><Reference><Citation>Auvigne, V., Tamandjou Tchuem, C. R., Schaeffer, J., Vaux, S. &amp; Parent Du Chatelet, I. Protection against symptomatic SARS-CoV-2 infection conferred by the Pfizer-BioNTech original/BA.4-5 bivalent vaccine compared to the mRNA original monovalent vaccines—a matched cohort study in France. Vaccine41, 5490–5493 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37541823</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson, N. W. et al. Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged &gt;/=50 years in Nordic countries: nationwide cohort study. BMJ382, e075286 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10364194</ArticleId><ArticleId IdType="pubmed">37491022</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilks, S. H. et al. Mapping SARS-CoV-2 antigenic relationships and serological responses. Science382, eadj0070 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37797027</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Straten, K. et al. Antigenic cartography using sera from sequence-confirmed SARS-CoV-2 variants of concern infections reveals antigenic divergence of Omicron. Immunity55, 1725–1731 e1724 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9353602</ArticleId><ArticleId IdType="pubmed">35973428</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury, D. S. et al. Correlates of protection, thresholds of protection, and immunobridging among persons with SARS-CoV-2 infection. Emerg. Infect. Dis.29, 381–388 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9881762</ArticleId><ArticleId IdType="pubmed">36692375</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury, D. S. et al. Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. Nat. Rev. Immunol.20, 727–738 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7605490</ArticleId><ArticleId IdType="pubmed">33139888</ArticleId></ArticleIdList></Reference><Reference><Citation>Auladell, M. et al. Influenza virus infection history shapes antibody responses to influenza vaccination. Nat. Med.28, 363–372 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35177857</ArticleId></ArticleIdList></Reference><Reference><Citation>Avumegah, M. S. et al. Availability and use of standards in vaccine development. NPJ Vaccines8, 95 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10313826</ArticleId><ArticleId IdType="pubmed">37391580</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentley, E. M. et al. Establishment of the 2nd WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin and Reference Panel for Antibodies to SARS-CoV-2 Variants of Concern. (19 July 2022); https://www.who.int/publications/m/item/who-bs-2022.2427</Citation></Reference><Reference><Citation>Carabelli, A. M. et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat. Rev. Microbiol.21, 162–177 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov, P. V. et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol.21, 361–379 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>ECDC. SARS-CoV-2 Variants of Concern as of 01 December 2023 (accessed 27 May 2024); https://www.ecdc.europa.eu/en/covid-19/variants-concern</Citation></Reference><Reference><Citation>IVAC. VIEW-hub (accessed 15 August 2023); https://view-hub.org/vaccine/covid/neutralization-studies</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>